Eli Lilly And Co LLY Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Sulzberger Gabrielle

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Luciano Juan R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Johnson Kimberly H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Hedley Mary Lynne

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Alvarez Ralph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

16

Price:

$750.77
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Sulzberger Gabrielle

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Luciano Juan R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

19

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Johnson Kimberly H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Hedley Mary Lynne

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Alvarez Ralph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

15

Price:

$762.66

Filings by filing date

Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Sulzberger Gabrielle

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Luciano Juan R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Johnson Kimberly H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Hedley Mary Lynne

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$750.77
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Alvarez Ralph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

16

Price:

$750.77
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Sulzberger Gabrielle

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Luciano Juan R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

19

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Johnson Kimberly H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Hedley Mary Lynne

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

13

Price:

$762.66
Mar 18, 2024 (filed on Mar 19, 2024)

Insider Name:

Alvarez Ralph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

15

Price:

$762.66

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	Lilly Corporate Ctr Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN 46285-0001
Tel:	N/A
Website:	https://www.lilly.com
IR:	See website

Key People

David A. Ricks Chairman of the Board, President, Chief Executive Officer	Johna L. Norton Executive Vice President - Global Quality	Anat Ashkenazi Chief Financial Officer, Executive Vice President
Diogo Rau Executive Vice President, Chief Information and Digital Officer	Daniel M. Skovronsky Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology	Alonzo Weems Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Anat Hakim Executive Vice President, General Counsel, Secretary	Eric Dozier Executive Vice President - Human Resources and Diversity	Edgardo Hernandez Executive Vice President, President - Manufacturing Operations
Patrik Jonsson Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA

Business Overview

Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Financial Overview

For the fiscal year ended 31 December 2023, Eli Lilly And Co revenues increased 20% to $34.12B. Net income decreased 16% to $5.24B. Revenues reflect Diabetes-Mounjaro segment increase from $482.5M to $5.16B, Oncology-Verzenio segment increase of 56% to $3.86B, U.S. segment increase of 20% to $21.79B, Europe segment increase of 44% to $6.17B. Net income was offset by Acquired in-Process Research and Deve increase from $908.5M to $3.8B (expense).

Employees:	43,000 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$736,104M as of Dec 31, 2023
Annual revenue (TTM):	$34,124M as of Dec 31, 2023
EBITDA (TTM):	$11,853M as of Dec 31, 2023
Net annual income (TTM):	$5,240M as of Dec 31, 2023
Free cash flow (TTM):	-$7,221M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$22,298M as of Dec 31, 2023
Shares outstanding:	950,766,100 as of Feb 28, 2024
Index Membership:	S&P 500
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization